This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

New Survey Of People Living With HIV Shows Desire For Greater Doctor-Patient Dialogue About Treatment And Disease Impact

Respondents selected that they would like to spend more time discussing how their current HIV drug treatment regimen is working (40 percent), other HIV treatment options (30 percent), health conditions they have other than HIV (30 percent), side effects of their current HIV medications (28 percent) and taking their current HIV treatment as directed (13 percent). Respondents also indicated that they would like to spend more time discussing the physical impact of HIV on their bodies (51 percent) and the impact of HIV on their sex lives (26 percent), day-to-day lives (25 percent), mental or emotional well-being (29 percent) and relationships with their loved ones or family (15 percent).

"As someone who has lived with HIV for close to 20 years, I know there are numerous topics to discuss during each visit to the doctor, and can understand why many people may find it difficult to cover all of them," said Duane Cramer, renowned photographer and I Design campaign spokesperson. "Preparing for discussions with my healthcare provider by prioritizing what I want to discuss about my medicines, my other health conditions and relevant aspects of my life have been important factors to my HIV treatment plan over the years. This is what I encourage people to do as part of the I Design campaign."

Additional Survey Findings

Preparation for Doctor's Appointments

  • 79 percent of respondents reported they did something to prepare for visits with their doctors over the past year; specifically:
    • 62 percent prepared a list of questions or topics to discuss, 32 percent conducted background research on topics other than HIV drug treatment options, 25 percent conducted background research on available HIV drug treatment options and 17 percent talked to others living with HIV
    • One in five (21 percent) respondents reported they did not do anything to prepare for visits with their doctors

Patient – Doctor Communication

  • Overall, respondents understand the information their doctor shares with them about the management of their HIV drug treatment:
    • 39 percent indicated that they understand all the information shared by their doctor about the management of their HIV drug treatment
    • 53 percent chose that they understand a great deal of this information
    • 8 percent selected that they understand some of the information
    • No respondents selected that they understand "very little" information
  • Of the topics listed in the survey related to drug treatment conversations, only 3 percent of respondents selected that they did not feel comfortable discussing any of them with their doctor; survey participants indicated that they are comfortable discussing with their doctor:
    • How their current HIV drug treatment regimen is working (88 percent)
    • Health conditions they have other than HIV (82 percent)
    • Side effects of their current HIV drug treatments (79 percent)
    • Taking their current HIV treatment as directed (77 percent)
    • Other HIV drug treatment options (72 percent)

Additional Sources of Information

  • 74 percent of respondents have referred to other resources in the past 12 months to help them better understand the management of their HIV condition, including HIV drug treatment:
    • 55 percent utilized online resources such as news, websites, blogs or forums; 27 percent used medication reminders/trackers or checklists; 26 percent employed the services of an AIDS Service Organization (ASO); 18 percent referred to support groups/services; and 20 percent used a resource other than those listed above
    • 26 percent didn't use any resources beyond what their doctor shares with them or tells them
  • Respondents who have utilized the services of an ASO (n = 211; 67 percent of total respondents) indicated that they accessed the following: HIV education (50 percent), counseling (47 percent), financial assistance (43 percent), testing (37 percent), food bank assistance (34 percent), legal services (27 percent), AIDS policy (19 percent), AIDS activism (18 percent), housing services (18 percent) and substance abuse treatment or counseling (9 percent)

About the Survey

The survey was conducted online by Kelton, an independent global insights firm, from July 2 – 29, 2013 among 316 people living with HIV who are on antiretroviral therapy. Respondents were 18 years of age and older, and had a median age of 49. About half (46 percent) of survey participants indicated having been diagnosed with HIV for more than 15 years. Respondents represented varying demographic areas (Northeast, Midwest, South and West) within the United States. Results of any sample are subject to sampling variation. Support for the research was provided by Merck, Whitehouse Station, NJ.

About I Design

I Design is a national HIV education campaign led by Merck, notable fashion designer Mondo Guerra and award-winning photographer Duane Cramer aimed at helping to empower people living with HIV to have open and meaningful discussions with their doctors about their treatment plan based on their medical and lifestyle needs.

To learn more about the campaign, visit www.ProjectIDesign.com where you can download a conversation checklist, which offers tips on how to engage in an open and honest dialogue with your doctor; design a digital textile illustrating your approach to managing HIV; and view videos and photos. To help you track and manage your health, there are the "My Health Matters" and "My Positive Agenda" mobile and desktop apps. These easy-to-use tools help you track the symptoms of your HIV, set up reminders to take your medications on time, and keep a record of when you have taken them, which can serve to prompt you on important discussion points when you are with your doctor. For additional tips and to follow Merck, Mondo, and Duane's collaboration on I Design, join them on Twitter @Merck, @LoveMondoTrasho and @DuaneCramer.

Merck's Commitment to HIV

For close to 30 years, Merck (NYSE: MRK) has been at the forefront of the response to the HIV epidemic, and has helped to make a difference through our proud legacy of commitment to innovation, collaborating with the community and expanding global access to medicines. In the United States, we are helping to address healthcare disparities through educational programs and resources that align with the National HIV Strategy. Merck is dedicated to applying our scientific expertise, resources and global reach to deliver healthcare solutions that support people living with HIV worldwide.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

SOURCE Merck

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,080.53 -17.92 -0.10%
S&P 500 2,002.56 -0.81 -0.04%
NASDAQ 4,588.9520 +8.6810 0.19%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs